Clinical outcomes in renal allograft recipients switched to long-term immunosuppressive therapy with mycophenolate mofetil after renal transplantation

Li-zhong CHEN,Zhi-hong LIU,Bing-yi SHI,Jiang-hua CHEN,Jian-yu LING,Wei ZHANG,Gen-fu ZHANG,Jian-hua AO,Yi-ping LU,Xiao-dong ZHANG,Yu FAN,Ye TIAN,Lu-lin MA,Li-ming WANG,Shun-liang YANG,Wu-jun XUE,Chang-sheng MING,Tong-yu ZHU,Da XU,Xiang-tie LI
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2012.12.005
2012-01-01
Abstract:Objective To document the impact of conversion to mycophenolate mofetil (MMF)at different time points after transplantation on the renal function of renal function.Methods A longterm,multicenter,non-interventional and observational study was done.Two cohorts were included:One was Switch cohort (340 cases) including renal allograft recipients who switched to MMF at least 6 months after renal transplantation and followed up for 4 years after switch; The other was Stay cohort (123 cases),including renal allograft recipients who received MMF treatment after transplantation and followed up for 4 years after enrollment.Results GFR values of patients in Switch cohort was significantly increased after switch,and the change in GFR slope was 3.1 mL· min-1 · year-1 (P<0.01).GFR values of patients in Stay cohort kept steady before and after enrollment,and the change in GFR slope was 0.44 mL·min-1 ·year-1 (P>0.05).Statistically significant difference in the onset time of GFR decline (defined as 20% decline from the baseline) was observed among subgroups within Switch cohort (P<0.01),but there was no significant difference among subgroups within Stay cohort (P>0.05).Stay cohort was 12% higher than in Switch cohort every year.Conclusion Conversion to MMF >6 months or even many years after transplantation can obviously improve the renal function of recipients.The earlier conversion can benefit improvement of the renal function.
What problem does this paper attempt to address?